LL-37 (Cathelicidin): What the Research Shows

The only human cathelicidin antimicrobial peptide — powerful immune defense with an uncomfortable cancer biology footnote

LL-37 occupies an unusual position among the compounds covered in this cluster: it is not an external research chemical in the conventional sense but an endogenous human protein—one your immune system produces right now, at every wound site, as part of the normal biological response to tissue damage and infection. This endogenous origin makes LL-37 one of the more scientifically grounded compounds in the tissue repair research space. It also means that understanding what LL-37 does requires a different frame than understanding a synthetic peptide with no natural biological context.

LL-37 is the only cathelicidin in humans—a class of antimicrobial peptides with ancient evolutionary origins in innate immunity. It is expressed by neutrophils, epithelial cells, and macrophages, and is released at sites of infection and tissue damage. Its functions span direct pathogen killing, immune cell recruitment, wound healing promotion, and inflammatory regulation. The research case for exogenous LL-37 administration rests on a straightforward premise: if deficiency impairs healing and defense, supplementation might help—particularly in conditions where endogenous LL-37 is known to be inadequate. What that premise lacks, at this stage of research, is human clinical trial data supporting it.

This article covers LL-37’s biology, its role in the innate immune system, the evidence across wound healing and infection models, the genuinely complicated relationship between LL-37 and cancer that any honest assessment must address, and the significant gap between the preclinical evidence base and human therapeutic applications.

Quick Facts

Peptide Name	LL-37 (hCAP18 C-terminal peptide; CAMP gene product)
Type	Endogenous human cathelicidin antimicrobial peptide; only human cathelicidin identified
Amino Acid Length	37 amino acids; N-terminal leucine-leucine (LL) gives the peptide its name
Molecular Weight	~4,493 g/mol
Parent Protein	hCAP18 (human cationic antimicrobial protein 18); LL-37 is the active C-terminal fragment released by protease cleavage
Gene	CAMP (cathelicidin antimicrobial peptide)
Primary Expression Sites	Neutrophil granules; epithelial cells (skin, gut, lung, oral mucosa, reproductive tract); macrophages; mast cells
Primary Research Areas	Wound healing, antimicrobial defense, innate immunity, diabetic ulcers, inflammatory skin conditions
Regulatory Status	Not approved for exogenous therapeutic use in any jurisdiction; research compound only
WADA Status	Not prohibited
Evidence Tier	PRECLINICAL ONLY  No published human trials of exogenous LL-37 administration

---

What Is LL-37?

LL-37 is a 37-amino-acid cationic peptide—the only cathelicidin found in humans. Its name derives from the two leucine (L) residues at its N-terminus and its length of 37 amino acids. It is produced endogenously by neutrophils, epithelial cells throughout the body, macrophages, and mast cells, and is released primarily in response to tissue damage, infection, and inflammatory signals.

LL-37 is not a discrete protein in the traditional sense—it is the biologically active C-terminal fragment of a precursor protein called hCAP18 (human cationic antimicrobial protein 18), encoded by the CAMP gene. hCAP18 is stored in neutrophil secondary granules and in epithelial cells. Upon activation by protease activity at sites of infection or inflammation, hCAP18 is cleaved to release LL-37 in its active form. This processing step is part of the normal biology and is relevant to understanding how endogenous LL-37 function differs from exogenous administration.

As a research compound, synthetic LL-37 is available through peptide suppliers. Its potential therapeutic applications center on two areas where endogenous LL-37 is known to play a role: wound healing and antimicrobial defense. In both contexts, the clinical rationale rests on observations that LL-37 deficiency correlates with impaired outcomes—delayed wound healing in diabetic patients, increased infection susceptibility in conditions like morbus Kostmann where LL-37 is absent. Whether exogenous LL-37 administration can therapeutically correct these deficiencies in humans has not been established in clinical trials.

LL-37’s biology also has a complicating dimension that distinguishes it from most other compounds in this cluster: its relationship with cancer. LL-37 is overexpressed in several tumor types and has been shown to promote tumor progression in some contexts while demonstrating anti-tumor activity in others. This dual role is not theoretical—it is documented in cell culture and animal studies—and represents a meaningful consideration for anyone evaluating LL-37 as a research compound. This is addressed in a dedicated section below.

---

Origins and Discovery

The cathelicidins as a family were identified in the late 1980s and early 1990s, as researchers began characterizing the antimicrobial peptide content of neutrophil granules. The name “cathelicidin” combines “cathepsin L inhibitor”—referring to a conserved N-terminal pro-domain present in all family members—with “cidin,” denoting antimicrobial activity. The family is widespread across vertebrates, with different species expressing different cathelicidin variants. Pigs have PR-39 and PMAP peptides. Cows have BMAP peptides. Mice have CRAMP (cathelin-related antimicrobial peptide). Humans have exactly one: LL-37.

LL-37 itself was first characterized in 1995 by Agerberth and colleagues, who identified and sequenced the active peptide from human neutrophil extracts. The same year, Gudmundsson and colleagues independently described the CAMP gene encoding hCAP18. These papers established LL-37 as the sole human cathelicidin and initiated a research program that has grown substantially over three decades.

Early research focused primarily on LL-37’s antimicrobial properties. The realization that LL-37 was also expressed by epithelial cells throughout the body, and that its expression was strongly upregulated at wound sites, expanded the field’s interest into wound healing and innate immune modulation. The discovery that patients with morbus Kostmann (severe congenital neutropenia) had virtually absent LL-37 in their oral mucosa and suffered devastating periodontal disease provided one of the first human genetic demonstrations of LL-37’s physiological importance.

Vitamin D’s role in LL-37 regulation added another important dimension in the 2000s. Studies established that 1,25-dihydroxyvitamin D3 (the active form of vitamin D) directly induces CAMP gene expression in human epithelial cells—a finding that linked vitamin D’s well-documented immune benefits to LL-37 induction. This means vitamin D status is a meaningful modulator of endogenous LL-37 levels, a fact relevant to understanding why LL-37 deficiency is observed more commonly in vitamin D-deficient populations.

---

LL-37 and the Cathelicidin Family: Evolutionary Context

Understanding LL-37’s biology benefits from appreciating its evolutionary context. Cathelicidins are among the most ancient components of vertebrate innate immunity—found across fish, amphibians, reptiles, birds, and mammals, suggesting an evolutionary origin predating the divergence of these lineages hundreds of millions of years ago. Their core function—disrupting microbial membranes through electrostatic interaction—is a fundamentally different antimicrobial strategy from the adaptive immune system’s antigen-specific responses, and one that pathogens have had great difficulty evolving resistance to.

The fact that humans retain only a single cathelicidin while other species express multiple variants is an interesting evolutionary puzzle. Rabbits express multiple cathelicidins with different antimicrobial spectra. Pigs have an extensive cathelicidin repertoire. The evolutionary consolidation to a single human cathelicidin may reflect compensation by other antimicrobial peptide families (defensins, particularly) or may represent a functional optimization under different selective pressures. What it means practically is that LL-37 carries an unusually broad functional load for a single molecule—it is the sole representative of its peptide class in human biology.

This evolutionary perspective is also relevant to the wound healing application. LL-37’s expression at wound sites is not incidental—it reflects a conserved biological function. Cathelicidins across species are upregulated in response to tissue damage, suggesting that the integration of antimicrobial defense with wound healing promotion represents an ancient, evolutionarily stable functional coupling. The wound healing effects of LL-37 are baked into its biology rather than being an incidental secondary effect discovered in laboratory screens.

---

Mechanism of Action

LL-37 is a multifunctional peptide with several mechanistically distinct activities that overlap and interact in ways that make it one of the more biologically complex compounds in this cluster.

Direct Antimicrobial Activity

LL-37 is a cationic amphipathic peptide—it carries a net positive charge and has both hydrophilic and hydrophobic domains along its alpha-helical structure. This architecture is the basis of its primary antimicrobial mechanism. Bacterial cell membranes carry a net negative charge, while mammalian cell membranes are predominantly zwitterionic (neutral). LL-37 selectively binds to negatively charged bacterial membranes through electrostatic attraction, inserts into the lipid bilayer, and disrupts membrane integrity—leading to leakage of cellular contents and bacterial death.

This mechanism confers broad-spectrum activity. LL-37 has demonstrated in vitro antimicrobial activity against gram-positive bacteria (Staphylococcus aureus, Streptococcus), gram-negative bacteria (Pseudomonas aeruginosa, E. coli), fungi (Candida), and certain enveloped viruses. The membrane-disruption mechanism is also why bacteria have had difficulty developing resistance to cathelicidins—mutations in bacterial membrane lipid composition sufficient to prevent LL-37 binding generally compromise bacterial viability.

Importantly, LL-37’s activity is sensitive to physiological conditions. High salt concentrations, low pH, and the presence of serum proteins can attenuate its direct antimicrobial activity in vitro. This salt sensitivity is a reason why in vitro antimicrobial data for LL-37 may overestimate its efficacy in vivo, where physiological salt concentrations differ from the low-salt buffers typically used in antimicrobial testing.

Wound Healing Promotion

LL-37 promotes wound healing through multiple cellular mechanisms. On keratinocytes—the primary epithelial cells responsible for wound re-epithelialization—LL-37 activates the epidermal growth factor receptor (EGFR) through a transactivation mechanism involving matrix metalloproteinase (MMP)-mediated shedding of EGFR ligands. EGFR activation in keratinocytes drives proliferation and migration, both essential for wound closure. LL-37 has also been shown to directly stimulate keratinocyte migration independent of EGFR in some systems.

Beyond keratinocytes, LL-37 promotes angiogenesis—the formation of new blood vessels essential for tissue repair. It activates formyl peptide receptor-like 1 (FPRL1/FPR2) on endothelial cells, stimulating VEGF production and endothelial cell migration. The combination of re-epithelialization promotion and angiogenesis induction makes LL-37 a mechanistically comprehensive wound healing agent, not just an antimicrobial that incidentally keeps wounds clean.

Immunomodulation: The Double-Edged Profile

LL-37’s immunomodulatory effects are genuinely bidirectional—it can be both pro-inflammatory and anti-inflammatory depending on context, concentration, and the cell types involved. This is not a flaw in understanding but an accurate description of a multifunctional molecule operating in different biological environments.

Pro-inflammatory effects include: mast cell activation with degranulation and histamine/prostaglandin release; dendritic cell maturation and promotion of Th1 immune responses; TLR4-mediated innate immune activation; and alarmin function—acting as an endogenous danger signal alerting the immune system to tissue damage.

Anti-inflammatory effects include: direct binding and neutralization of lipopolysaccharide (LPS), preventing TLR4 activation and endotoxin-driven inflammation; suppression of LPS-induced TNF-alpha production in macrophages; and promotion of resolution-phase mediator production in some contexts.

The net immunomodulatory effect of LL-37 in any given tissue context depends on which of these effects predominates—a complexity that makes predicting the consequences of exogenous administration in specific disease states difficult without human data.

Receptor Interactions

LL-37 interacts with multiple receptors, contributing to its pleiotropic effects. Key receptor interactions include FPRL1/FPR2 on leukocytes and endothelial cells (chemotaxis and angiogenesis); P2X7 purinergic receptor (inflammasome activation); EGFR transactivation in epithelial cells (wound healing); TLR4 and TLR9 (innate immune activation and LPS neutralization); and direct membrane interactions for antimicrobial activity. This promiscuous receptor engagement makes LL-37 more difficult to characterize pharmacologically than compounds with a single primary receptor, and it means that off-target effects—including those relevant to tumor biology—are mechanistically plausible and documented.

---

Key Research Areas and Studies

Wound Healing and Diabetic Ulcers

The wound healing research for LL-37 is among the most compelling in this cluster, and for a specific reason: it is genuinely deficient in the wound context where its absence causes the most clinically significant harm—diabetic foot ulcers. Diabetic patients show impaired induction of LL-37 expression in wound tissue compared to non-diabetic controls, and this deficiency correlates with the delayed healing and elevated infection risk that characterizes diabetic wounds. High glucose levels impair CAMP gene expression in keratinocytes, reducing LL-37 production at wound sites—a documented biological mechanism, not a speculative association.

In diabetic mouse models, topical application of exogenous LL-37 has consistently demonstrated accelerated wound closure, improved re-epithelialization, and reduced bacterial colonization. Studies using streptozotocin-induced diabetic mice—where LL-37 deficiency at wound sites has been confirmed—showed that LL-37 treatment restored closure rates toward those of non-diabetic controls. The EGFR transactivation mechanism is central to these results: studies blocking EGFR signaling before LL-37 treatment largely abolished the wound closure acceleration, confirming the specific pathway involved.

Morbus Kostmann provides a human genetic model of LL-37 deficiency. Patients with this rare congenital neutropenia have virtually absent LL-37 in their oral mucosa and suffer severe periodontal disease beginning in early childhood. Treatment with G-CSF that restores neutrophil counts also restores oral LL-37 levels and dramatically improves periodontal outcomes. This human genetic evidence—while not a controlled trial of exogenous LL-37—provides the strongest direct human evidence that LL-37 deficiency causes clinically meaningful harm.

Antimicrobial Applications

LL-37’s antimicrobial spectrum has been extensively characterized in vitro against clinically relevant pathogens including MRSA, Pseudomonas aeruginosa, Candida albicans, and several respiratory viruses. The activity against multidrug-resistant organisms has generated interest in LL-37 as a potential antibiotic adjunct or alternative in the context of the antimicrobial resistance crisis.

A synthetic LL-37 analog, SAAP-148, has shown potent activity in mouse skin infection models against MRSA and multidrug-resistant Acinetobacter baumannii—including organisms resistant to existing topical antibiotics. This represents some of the closest-to-clinical-translation work in the LL-37 space, though it involves a modified analog rather than native LL-37. The distinction matters: SAAP-148 and other analogs are specifically engineered for improved stability and selectivity, and their clinical development does not confer any therapeutic validation to the native peptide.

Inflammatory Skin Conditions

In psoriasis, LL-37 levels are elevated and the peptide has been identified as a key trigger of the innate immune activation that drives the psoriatic inflammatory cascade. LL-37 forms complexes with self-DNA at psoriatic plaques that activate plasmacytoid dendritic cells via TLR9 and TLR7, driving type I interferon production—a central driver of psoriatic inflammation. In rosacea, LL-37 has similarly been identified as a disease driver rather than a therapeutic target, with abnormal cathelicidin peptide processing triggering the neurovascular responses characteristic of rosacea.

These findings have direct practical implications: in conditions characterized by excessive cathelicidin activity, adding exogenous LL-37 would theoretically worsen rather than improve outcomes. Psoriasis and rosacea are clear contraindications for exogenous LL-37 use.

Respiratory Infections and Innate Defense

LL-37 is expressed in lung epithelium and is a component of innate immune defense in the respiratory tract. The cystic fibrosis research context has been particularly notable: the high-salt airway surface liquid in CF airways inhibits LL-37 activity (consistent with its salt sensitivity), contributing to the infection susceptibility that defines CF morbidity. During viral respiratory infections, LL-37 expression is upregulated, and several studies have demonstrated antiviral activity against influenza A, RSV, and SARS-CoV-2 in vitro. COVID-19 pandemic research generated renewed interest in LL-37’s antiviral properties, though observational associations between vitamin D, LL-37, and COVID-19 outcomes are hypothesis-generating rather than evidence of therapeutic efficacy.

---

The Cancer Complication: A Necessary Detour

Any honest overview of LL-37 must address its relationship with cancer directly and in detail. This is not a theoretical concern based on mechanism alone—it is documented in cell culture and animal studies—and it represents the most significant practical consideration distinguishing LL-37 from other compounds in this cluster.

Pro-Tumorigenic Evidence

LL-37 is overexpressed in ovarian cancer tissue and has been shown to promote ovarian cancer cell proliferation and migration in vitro. The mechanism involves EGFR and HER2 transactivation—the same pathway through which LL-37 promotes keratinocyte migration in wound healing. In ovarian cancer cells, this pathway drives tumor cell growth. Studies in mouse xenograft models showed that exogenous LL-37 accelerated ovarian tumor growth and promoted metastasis.

In lung cancer, LL-37 has been identified as a mediator of cancer-associated stromal signaling. Tumor-associated fibroblasts in non-small cell lung cancer express elevated LL-37, which acts on neighboring cancer cells to promote epithelial-mesenchymal transition (EMT)—a process associated with increased invasiveness and metastatic potential. In certain breast cancer subtypes, LL-37 promotes cancer cell survival through FPRL1-mediated signaling, and elevated tumor LL-37 expression has been associated with worse outcomes in some patient subgroups.

Anti-Tumorigenic Evidence

The picture is not uniformly pro-tumorigenic. In colorectal cancer, LL-37 has shown anti-tumor activity—inhibiting cancer cell proliferation and inducing apoptosis—and its expression is actually downregulated in colorectal tumors compared to normal mucosa. In leukemia and lymphoma models, LL-37 has demonstrated direct cytotoxic effects on malignant cells. Some melanoma and prostate cancer studies have found anti-proliferative effects.

What This Means Practically

The cancer data does not resolve to a simple conclusion. LL-37’s oncological effects appear to be cancer-type specific, concentration-dependent, and context-dependent. What it does mean is that exogenous LL-37 administration is not pharmacologically neutral with respect to cancer biology. In individuals with existing malignancy or elevated cancer risk in types where pro-tumorigenic effects have been documented (ovarian, lung, certain breast cancers), the cancer biology of LL-37 is a material consideration that warrants explicit discussion with a physician before any use.

Without controlled human studies examining the oncological effects of exogenous LL-37, the net cancer risk—including in healthy individuals with undiagnosed subclinical malignancy—cannot be characterized. Preclinical data establishes a plausible concern; it does not quantify the risk in humans. This is one of the most significant ways in which the absence of Phase I trial data for LL-37 is consequential rather than merely inconvenient.

---

Common Claims versus Current Evidence

Claim	Current Evidence
“Accelerates wound healing”	Supported by preclinical data, particularly in diabetic wound models where LL-37 deficiency is documented and the EGFR transactivation mechanism is well-characterized. Human clinical trial evidence for exogenous administration does not exist. The strongest human evidence is genetic—LL-37 deficiency in morbus Kostmann causes harm; restoring it reverses harm. This is not the same as evidence that exogenous LL-37 improves healing in people with normal endogenous levels.
“Kills antibiotic-resistant bacteria”	Demonstrated in vitro against MRSA and other drug-resistant organisms. Animal infection model data is supportive. Salt sensitivity limits in vivo activity relative to in vitro data. Modified LL-37 analogs—not native LL-37—are in early clinical development for topical antimicrobial applications. Native LL-37 has no approved antimicrobial indication.
“Boosts immune function”	LL-37’s immunomodulatory effects are bidirectional and context-dependent. It drives pathological inflammation in psoriasis and rosacea. “Boosts immune function” is an oversimplification of a complex regulatory role that can be beneficial or harmful depending on the specific immune context.
“Safe because it’s natural or endogenous”	Endogenous origin does not confer safety at exogenous doses. LL-37 is a driver of psoriasis and rosacea pathology despite being natural. Its documented pro-tumorigenic effects in ovarian, lung, and some breast cancers represent a meaningful safety consideration not addressed by its natural origin. This argument is consistently misused across peptide research discussions.
“Effective against viral infections including COVID-19”	Antiviral activity demonstrated in vitro for influenza A, RSV, and SARS-CoV-2. Observational associations between vitamin D status, LL-37 levels, and COVID-19 outcomes exist but do not establish causation or support exogenous LL-37 as a treatment. No controlled clinical data exists for LL-37 as an antiviral in any indication.

---

The Human Evidence Landscape

There are no published Phase I, II, or III clinical trials examining exogenous LL-37 administration in human subjects for any indication. There are no published human pharmacokinetic studies for exogenous LL-37. The human evidence for LL-37’s biological importance is extensive—correlation studies, genetic deficiency models, tissue expression data across disease states—but all of this evidence concerns endogenous LL-37 behavior, not the effects of exogenous administration.

This distinction matters more for LL-37 than for most compounds in this cluster. With synthetic research compounds that have no endogenous counterpart, the absence of human data simply means efficacy and safety are unknown. With LL-37, there is an additional layer: the compound is already present in human biology at carefully regulated concentrations and spatial distributions. Exogenous administration bypasses those regulatory mechanisms and delivers LL-37 at potentially supraphysiological levels, through routes that differ substantially from natural release patterns at sites of infection and tissue damage.

The cancer biology concern makes this gap particularly consequential. In a Phase I trial, safety is prospectively monitored in a controlled population with defined endpoints, regular biomarker monitoring, and established stopping rules for emerging safety signals. Without that data, the oncological risk of exogenous LL-37 in humans with undiagnosed malignancy or elevated cancer risk is entirely uncharacterized. This is not a concern that can be assessed from preclinical data alone or from uncontrolled community self-experimentation.

---

Safety, Risks, and Limitations

Cancer Risk: The Primary Safety Concern

The pro-tumorigenic effects documented in ovarian, lung, and certain breast cancer contexts are a genuine concern that should be taken seriously. Anyone with a personal or family history of these cancers, or with other elevated cancer risk factors, should consider this evidence material to any decision about exogenous LL-37. The absence of human clinical trial data means the actual risk in humans cannot be quantified. This warrants explicit discussion with a physician rather than self-assessment.

Inflammatory Skin Conditions: Clear Contraindications

LL-37 drives the psoriatic and rosacea inflammatory cascades. Both conditions are clear contraindications for exogenous LL-37 administration. In both cases, the therapeutic direction is toward reducing cathelicidin activity, not augmenting it. Exogenous LL-37 in these patients would be expected to worsen disease.

Concentration-Dependent Cytotoxicity

LL-37’s membrane-disruption mechanism is selective for bacterial membranes at physiological concentrations, but at supraphysiological concentrations it can disrupt mammalian cell membranes and produce cytotoxic effects. This concentration-dependent cytotoxicity is well-documented in vitro: keratinocyte EGFR activation and migration are stimulated at low micromolar concentrations (~0.5-5 mcM), while cytotoxicity emerges above approximately 20 mcM. The therapeutic window between beneficial and cytotoxic concentrations is not characterized in humans.

Mast Cell Activation

LL-37 activates mast cells, triggering degranulation and release of histamine, prostaglandins, and other vasoactive mediators. This is relevant in individuals with mast cell activation syndrome (MCAS) or elevated baseline mast cell reactivity, where exogenous LL-37 could trigger mast cell-mediated reactions including urticaria, flushing, and systemic inflammatory symptoms. The flushing occasionally reported in community self-experimentation is consistent with this mechanism.

Aggregation and Supply Quality

LL-37’s amphipathic character makes it prone to aggregation in solution at higher concentrations. Aggregated peptide has different biological activity and bioavailability from monomeric peptide. Supplier quality control—including purity confirmation by mass spectrometry and endotoxin testing—is a meaningful practical consideration for any injectable research use. Endotoxin contamination in LL-37 preparations would produce inflammatory responses through the very TLR4 signaling that LL-37 is known to engage, potentially confounding any research observations.

---

Legal and Regulatory Status

United States

LL-37 is not approved by the FDA for any therapeutic indication and is not listed on the FDA’s bulk drug substance lists as of this writing. It is available through research peptide suppliers. Several LL-37 analogs are in early-stage clinical development, but these are distinct modified compounds; their development does not confer regulatory standing to native LL-37.

International

No regulatory authority in any major jurisdiction has approved LL-37 for therapeutic use. Its international status mirrors the US situation—a research compound in a regulatory gray area in most markets. Jurisdiction-specific verification is the reader’s responsibility.

WADA Status

LL-37 is not on the WADA Prohibited List and is not prohibited in competitive sport. Athletes subject to anti-doping testing should verify current status against the annual WADA prohibited list.

---

Research Protocols and Laboratory Practices

This section describes handling and administration practices from the published research literature and is provided for research context only.

Form and Reconstitution

Synthetic LL-37 is supplied as a lyophilized powder. Given its amphipathic character, LL-37 can aggregate in solution at higher concentrations—a practical consideration in research settings. It is typically reconstituted in sterile water, low-concentration acetic acid (0.1%), or PBS depending on the specific application. For antimicrobial studies, low-salt buffers are often used to maximize activity. Confirming peptide solubilization and monitoring for aggregation is important; aggregated peptide has different biological activity from monomeric peptide.

Storage

Lyophilized LL-37 is stable at 2-8°C (35-46°F) and may be stored at -20°C (-4°F) for extended periods. Reconstituted solutions should be used promptly and stored at 4°C only for short-term use. Repeated freeze-thaw cycles accelerate degradation and may promote aggregation. Protection from light is advisable. Endotoxin testing of the supplier’s product is a meaningful quality check for injectable applications.

Routes of Administration in Research

Research applications use multiple routes. Topical application is the most common in wound healing and dermatological studies, is the most direct route for localized applications, and is the route most consistent with the preclinical evidence base. Subcutaneous and intraperitoneal injection have been used in systemic infection and immune studies in animals. Intranasal delivery has been explored for respiratory infection models. The relevance of animal study routes to the human context varies considerably by application, and systemic injection departs substantially from the localized, on-demand biological context in which endogenous LL-37 normally operates.

---

Dosing in Published Research

Study / Model	Population	Dose	Route	Duration	Key Findings
Diabetic wound healing (multiple groups)	STZ-diabetic mice	1-10 mcg per wound site	Topical	7-14 days	Accelerated wound closure; improved re-epithelialization; reduced bacterial colonization; consistent across multiple studies
Keratinocyte EGFR activation (in vitro)	Human keratinocyte cell lines	0.5-5 mcM (~2-22 mcg/mL)	In vitro	Acute	Stimulates migration via EGFR transactivation; cytotoxic effects emerge above ~20 mcM—establishes practical concentration ceiling
Pseudomonas lung infection (CF model)	Pseudomonas-infected mice	0.5-2 mg/kg intratracheal	Intratracheal	Single dose or 3-day course	Reduced bacterial burden in lung; activity attenuated in high-salt airway fluid (CF-relevant finding)
MRSA skin infection (SAAP-148 analog)	MRSA-infected mice	0.16% gel, topical	Topical	4 days	Eradicated drug-resistant MRSA—note: SAAP-148 is a modified LL-37 analog, not native LL-37. Results do not directly transfer to native peptide.
LPS-induced systemic inflammation	Mice	1-5 mg/kg IV or IP	IV / IP	Acute	LPS neutralization and reduced cytokine release documented; demonstrates the direct LPS-binding mechanism

---

Dosing in Independent Self-Experimentation Communities

Protocol Parameter	Typical Community Range	Notes
Dose per administration	100-500 mcg	No validated human dose-finding data; extrapolated from animal studies with significant uncertainty
Route	Subcutaneous injection; topical for wounds	Topical application is most consistent with the preclinical evidence for wound healing; systemic SC injection departs substantially from the localized biological context in which endogenous LL-37 normally operates
Frequency	Daily to every other day	Driven by short half-life rationale; no validated human dosing interval
Primary reported uses	Wound healing adjunct, infection prevention, immune support	Wound healing is the most mechanistically coherent with the preclinical evidence; systemic immune support use is more speculative
Reported adverse effects	Injection site reactions; occasional flushing (consistent with mast cell activation)	The cancer biology and mast cell concerns would not be captured by community self-reporting over typical self-experimentation timescales. Absence of reports is not a safety characterization.

---

Frequently Asked Questions

What does LL-37 stand for?

LL-37 takes its name from its structure: the “LL” refers to the two leucine (L) residues at its N-terminus, and “37” refers to its length of 37 amino acids. It is the active C-terminal fragment of a larger precursor protein called hCAP18 (human cationic antimicrobial protein 18), released by protease cleavage at sites of infection and inflammation.

Is LL-37 endogenous—does my body already make it?

Yes. LL-37 is a naturally occurring human peptide produced by neutrophils, skin cells, gut epithelium, lung epithelium, and other tissues. It is released at wound sites and sites of infection as a normal component of innate immune defense. The research interest in exogenous LL-37 is based on the observation that endogenous levels are inadequate in certain disease states, particularly diabetic wounds. Whether exogenous administration corrects these deficiencies in humans has not been established in clinical trials.

Should people with cancer history be concerned about LL-37?

The preclinical evidence for pro-tumorigenic effects in ovarian, lung, and certain breast cancers is a genuine concern that should be taken seriously. Anyone with personal or family history of these cancers, or with other elevated risk factors, should consider this evidence material to any decision about exogenous LL-37. The absence of human clinical trial data means the actual risk cannot be quantified. This question warrants explicit discussion with a physician.

Can LL-37 treat antibiotic-resistant infections?

LL-37 demonstrates activity against MRSA and other antibiotic-resistant organisms in laboratory settings and animal models. It does not “treat” infections in any clinically validated sense—there are no approved LL-37 preparations for human use. Modified LL-37 analogs—not native LL-37—are in early clinical development for topical antimicrobial applications. Native LL-37’s activity is also attenuated in physiological salt concentrations, limiting in vivo efficacy relative to in vitro data.

Does vitamin D increase LL-37?

Yes—this is one of the better-characterized regulatory relationships in innate immune biology. The active form of vitamin D directly induces CAMP gene expression in human epithelial cells, increasing LL-37 production. Vitamin D deficiency is associated with reduced mucosal LL-37 levels and increased susceptibility to certain infections. Optimizing endogenous LL-37 through vitamin D sufficiency is a very different and substantially lower-risk intervention than exogenous LL-37 administration, and does not carry the same safety considerations.

Can people with psoriasis or rosacea use LL-37?

No. LL-37 is a documented driver of psoriatic inflammation—it forms complexes with self-DNA at psoriatic plaques that activate innate immune cells and sustain the inflammatory cascade. In rosacea, abnormal LL-37 processing generates peptide forms that trigger neurovascular responses characteristic of the disease. In both conditions, therapeutic efforts focus on reducing cathelicidin activity, not augmenting it. Exogenous LL-37 is contraindicated in both contexts.

Has LL-37 been tested in humans?

There are no published Phase I, II, or III clinical trials of exogenous LL-37 administration. Extensive human observational data exists documenting endogenous LL-37 levels in various disease states, and genetic models like morbus Kostmann provide human evidence of LL-37’s physiological importance. But controlled studies of exogenous LL-37 in humans do not exist. Some LL-37 analogs are in early clinical development—these are modified versions engineered for specific applications, distinct from native LL-37.

---

Related Peptides: How LL-37 Compares

LL-37 is mechanistically distinct from all other compounds in the Injury Recovery and Tissue Repair cluster. Its primary biological identity is antimicrobial and innate immune—it belongs to the front-line defense layer of human biology, not the growth-factor-mediated repair layer. The wound healing effects are real but are arguably secondary to the evolutionary function of pathogen defense at wound sites. It is the only compound in this cluster with documented pro-tumorigenic effects and clear contraindications in specific inflammatory skin conditions.

Feature	LL-37	BPC-157	KPV	Thymosin Alpha-1
Primary mechanism	Membrane disruption (antimicrobial); EGFR transactivation (wound); LPS neutralization; bidirectional immune modulation	Angiogenesis; VEGF/EGR-1; NO signaling; cytoprotection	MC1R/MC3R agonism; NF-kB inhibition; NLRP3 suppression	TLR2/TLR9 signaling; T-cell maturation; Th1 polarization
Endogenous?	Yes—only human cathelicidin	No—synthetic gastric-derived peptide	Yes—C-terminal fragment of alpha-MSH	Yes—thymic epithelial cell product
Evidence tier	PRECLINICAL	PILOT	PRECLINICAL	APPROVED DRUG
Unique safety concern	Documented pro-tumorigenic effects in ovarian, lung, certain breast cancers; clear contraindication in psoriasis and rosacea; mast cell activation; concentration-dependent cytotoxicity	Single-group research concentration; no RCT data	Theoretical immunosuppression; MC4R nausea at higher doses	Risk in autoimmune conditions; TESTS sepsis RCT primary endpoint failure
WADA status	Not prohibited	Prohibited (S0)	Not prohibited	Not prohibited
Closest translational path	Modified analogs (SAAP-148) in early clinical development for topical antimicrobial use—not native LL-37	IBD Phase II initiated historically; no active known program	Nanoparticle delivery for IBD—academic stage	Already approved; US path requires NDA filing

What the comparison reveals: LL-37 has the most biologically distinctive profile and the most substantive safety concerns of any compound in this cluster. Its wound healing evidence in the diabetic ulcer context is mechanistically the most compelling of the preclinical-only compounds here. But the cancer biology, the clear contraindications in psoriasis and rosacea, and the bidirectional immunomodulatory effects put it in a different risk category from KPV or even BPC-157. The preclinical evidence tier is accurate—but the safety considerations are more complex than that tier designation alone conveys.

---

Summary and Key Takeaways

• LL-37 is the only human cathelicidin—an endogenous 37-amino-acid antimicrobial peptide produced by neutrophils and epithelial cells as part of innate immune defense.
• Its functions span broad-spectrum antimicrobial activity through membrane disruption, wound healing promotion through EGFR transactivation and angiogenesis, LPS neutralization, and bidirectional immunomodulation—making it one of the most multifunctional compounds in this cluster.
• Wound healing evidence is among the more mechanistically compelling preclinical cases, particularly for diabetic wounds where LL-37 deficiency is documented and the correction mechanism is specific. The morbus Kostmann genetic model provides direct human evidence of physiological importance.
• There are no published human clinical trials of exogenous LL-37 administration. The evidence base is entirely preclinical and observational.
• LL-37 has documented pro-tumorigenic effects in ovarian, lung, and certain breast cancer contexts. This is the most significant safety consideration distinguishing LL-37 from other compounds in this cluster.
• LL-37 drives pathological inflammation in psoriasis and rosacea. Both conditions are clear contraindications for exogenous use.
• Vitamin D sufficiency directly supports endogenous LL-37 production through CAMP gene induction—a substantially lower-risk approach to supporting the LL-37 pathway than exogenous administration.
• Modified LL-37 analogs—not native LL-37—are in early clinical development for topical antimicrobial applications. These are distinct compounds engineered for specific applications.
• Community use is less common than other cluster compounds, and the cancer biology concern is more widely acknowledged in LL-37 community discussions than for most other peptides.
• WADA does not prohibit LL-37. It is not FDA-approved for any use.

---

Selected References and Key Studies

• Agerberth B, Gunne H, Odeberg J, et al. “FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis.” Proceedings of the National Academy of Sciences. 1995;92(1):195-199.
• Gudmundsson GH, Agerberth B, Odeberg J, et al. “The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes.” European Journal of Biochemistry. 1996;238(2):325-332.
• Heilborn JD, Nilsson MF, Kratz G, et al. “The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium.” Journal of Investigative Dermatology. 2003;120(3):379-389.
• Sorensen OE, Cowland JB, Theilgaard-Monch K, et al. “Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors.” Journal of Immunology. 2003;170(11):5583-5589.
• Coffelt SB, Marini FC, Watson K, et al. “The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells.” Proceedings of the National Academy of Sciences. 2009;106(10):3806-3811.
• Liu PT, Stenger S, Li H, et al. “Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.” Science. 2006;311(5768):1770-1773.
• Lande R, Gregorio J, Facchinetti V, et al. “Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide.” Nature. 2007;449(7162):564-569.
• Zanetti M. “Cathelicidins, multifunctional peptides of the innate immunity.” Journal of Leukocyte Biology. 2004;75(1):39-48.
• de Breij A, Riool M, Cordfunke RA, et al. “The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms.” Science Translational Medicine. 2018;10(423).
• Duplantier AJ, van Hoek ML. “The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds.” Frontiers in Immunology. 2013;4:143.

---

Further Reading and References

• ClinicalTrials.gov—Search “LL-37” or “cathelicidin” for registered trials: clinicaltrials.gov
• WADA Prohibited List—Annual publication: wada-ama.org
• Peptidings—BPC-157 Research Overview
• Peptidings—KPV Research Overview
• Peptidings—Thymosin Alpha-1 Research Overview
• Peptidings—Injury Recovery and Tissue Repair Research Cluster
• Peptidings—Peptides Studied for Wound Healing
• Peptidings—Peptides Studied for Inflammation and Autoimmune Conditions
• Peptidings—Peptide Research Glossary—definitions for cathelicidin, EGFR, LPS, keratinocyte, MRSA, mast cell, and other terms used in this article